Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Topaz Pharmaceuticals has secured $20 million in series A venture financing from Aisling Capital, New York and Fidelity Biosciences, Boston.
Subscribe to our email newsletter
This latest round of funding was conducted with financial advice from Seaview Securities and advised by Fox Rothschild Technology and Venture Finance Group.
The funds will be used to help Topaz complete clinical trials of the company’s new prescription medicine to fight head lice, and prepare the product for market.
Nick Spring, president and CEO of Topaz Pharmaceuticals, said: “This round of funding is a significant milestone in the evolution of Topaz Pharmaceuticals.”